Jim Cramer knows that many of the FANG faithful are tempted to sell. He makes the case as to why Facebook, Amazon, Netflix & Google could still surge.» Read More
Companies are making headlines after the bell Tuesday:
OPEC is no longer a "viable entity" following its refusal to cut oil production, Dennis Gartman told CNBC.
As stocks slide today, CNBC's Jim Cramer explains what's leading today's market decline.
Is it smarter to own a home or to buy into the stock market? We have the data and the experts weigh in.
One of the primary investing trends in the post-crisis market is breaking down, providing an opportunity for stock picking.
Toss 'em in your kids' stocking, or be a Grinch and keep them. "Mad Money" host Jim Cramer says buy 'em either way.
The Shanghai Composite recorded its biggest drop in about five years as the oil price slide continued to weigh on Middle East indices.
Wharton professor Jeremy Siegel tells CNBC he expects a correction but still remains bullish overall.
Southwest Airlines appears to be one of the biggest winners of oil's slide.
Some of the names on the move ahead of the open.
Drug giant Merck said it will buy Cubist and its slate of medicines administered in hospitals, many for bacterial infections, for about $9.5 billion.
The Fast Money traders share their final trades of the day and what they'll be trading tomorrow.
The "Black Card" is just one of many elite credit cards offering special incentives to cardholders.
Jim Cramer sits down with Enbridge CEO Albert Monaco to discuss the way to play crude in a low priced environment.
Jim Cramer has a personal connection to why he approves of Merck's acquisition of Cubist. Find out why.
Goldman Sachs already appears to be having second thoughts on its tepid forecast for 2015.
Check out which companies are making headlines after the bell Monday: H&R Block, Verizon, United Airlines and more.
Buying a call is one of the simplest options strategies. So how, exactly, does it work?
Consumers are choosing Apple's high-end iPhones with more memory as they shoot and consume more video, according to Citigroup.
Three small-cap drug firms are consistently the best biotech performers following the start of the American Society of Hematology's annual meeting.